A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.

A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01884974

Acronym

PH-MPD1

Enrollment

150

Registered

2013-06-24

Start date

2013-07-31

Completion date

Unknown

Last updated

2015-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloproliferative Disease, Pulmonary Hypertension

Keywords

Myeloproliferative disease, Pulmonary Hypertension

Brief summary

Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates. The purpose of this research: 1. Assess Prevalence of PH in patients with CMPD in Northern Israel 2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Detailed description

study will include the following: * sex * age * BMI * ethnicity * age diagnosed with Myeloproliferative disease * clinical manifestations of the myeloproliferative disease * JAK2 mutation * known hematological complications

Interventions

OTHERmyeloproliferative disease

Echocardiogram, demographic data, St George respiratory questioner

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1\) consenting patients diagnosed with a myeloproliferative disease

Exclusion criteria

1\) Refusal to have an echocardiogram or answer the St. George respiratory questionnaire

Design outcomes

Primary

Measure	Time frame	Description
pulmonary hypertension	1 year	all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram. Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg.

Secondary

Measure	Time frame
St George Respiratory Questionnaire	1 year

Countries

Israel

Contacts

Primary ContactShoshan Perek, MD

shoshanpe@clalit.org.il972-4-8250517

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026